1. Inicio
  2. Publicaciones
  3. Characteristics and clinical outcomes of a nationwide cohort of patients with small cell lung cancer following first-line treatment: Real-world evidence

Characteristics and clinical outcomes of a nationwide cohort of patients with small cell lung cancer following first-line treatment: Real-world evidence

Fecha de publicación:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Ospina-Serrano A.V.
  • Cobo M.
  • Calvo V.
  • Cantero A.
  • García Campelo R.
  • López Castro R.
  • Carcereny E.
  • Olivares A.
  • Rodríguez-Abreu D.
  • Barnabé R.
  • Bosch-Barreri J.
  • Massutí B.
  • Sánchez-Hernandez A.
  • Ortega A.L.
  • Lázaro-Quintana M.
  • Guirado M.
  • Vázquez S.
  • Espinosa P.
  • Provencio M.

Grupos

Abstract

Background: Patients with small cell lung cancer (SCLC) have an unfavorable prognosis. Our aim was to describe characteristics and clinical outcomes of a nationwide cohort of patients. Methods: Multicenter, observational, ambispective study based on the Spanish Thoracic Tumor Registry. From August 2016 to June 2023, patients aged = 18 with SCLC undergoing oncological treatment following first-line therapy were eligible. Descriptive statistical analyses, cox proportional hazards model, and Kaplan-Meier survival curves were performed. Results: 1,284 patients were included. 941 (73.3%) were men. The median age was 63.2 years. 68.1% had extensive-stage disease (ES-SCLC) at diagnosis, 87.9% had Eastern Cooperative Oncology Group (ECOG) 0–1, 90.8% received first-line platinum-based chemotherapy. The median chemotherapy-free interval (CTFI) was 230.5 days for patients with limited-stage disease (LS-SCLC) at diagnosis and 100 days for those with ES-SCLC. After a median follow-up of 72.6 months, the median progression-free survival (PFS) was 5.8 months for patients with LS-SCLC versus 4.6 months for those with ES-SCLC, HR 1.22p 0.010. The median overall survival (OS) was 16.5 months in patients with CTFI = 90 versus 10.2 months in those with CTFI < 90 (p < 0.001). Factors associated with OS were ES-SCLC (HR: 1.57, p < 0.01), ECOG ?2 (HR: 1.43, p 0.03), CTFI ?90 (HR: 0.34, p < 0.001), and CTFI ?180 (HR: 0.20, p < 0.01). Conclusions: Clinical outcomes are poor in our patients, with slightly better results for those with chemotherapy-sensitive disease. Factors influencing prognosis include tumor extent, performance status, and CTFI. New treatment options are required to improve survival in this oncological population. © 2026 Elsevier B.V.

Datos de la publicación

ISSN/ISSNe:
0169-5002, 1872-8332

LUNG CANCER  ELSEVIER IRELAND LTD

Tipo:
Article
Páginas:
-
PubMed:
42217422
Enlace a otro recurso:
www.scopus.com
Factor de Impacto:
1,399 SCImago ℠
Cuartil:
Q1 SCImago ℠

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Small Cell Lung Carcinoma; Treatment Outcome; antineoplastic metal complex; cyclophosphamide; doxorubicin; gemcitabine; irinotecan; paclitaxel; topotecan; vincristine; antineoplastic agent; adult; age; aged; Article; cancer chemotherapy; cancer diagnosis; cancer immunotherapy; cancer patient; cancer prognosis; cancer registry; cancer staging; cancer survival; chemotherapy free interval; clinical feature; clinical outcome; cohort analysis; ECOG Performance Status; female; first-line treatment; follow up; hazard ratio; human; Kaplan Meier method; major clinical study; male; middle aged; observational study; overall survival; progression free survival; proportional hazards model; retrospective study; risk factor; second-line treatment; small cell lung cancer; statistical analysis; time interval; treatment duration; treatment response; clinical trial; drug t

Cita

Compartir